touchCONGRESS for touchONCOLOGY
Listen to Dr Esther Oliva (Italy) review key data presented at the EHA 2022 Hybrid Congress on recent developments in the treatment of higher-risk MDS and newly diagnosed AML; she offers her expert insights on their potential impact on future clinical practice, alongside those from Prof. Michael Heuser (Germany) and Dr Yishai Ofran (Israel).
- Data review with Dr Oliva (0:00)
Expert interviews with Prof. Heuser, Dr Ofran and Dr Oliva, answering the questions below- Based on data presented at EHA 2022, which emerging treatments are most likely to impact future clinical practice for patients with HR-MDS? (30:08)
What do the latest data presented at EHA 2022 tell us about the clinical relevance of TP53 mutation in HR-MDS and newly diagnosed AML? (35:47)To what extent will lower-intensity treatment regimens improve patient outcomes in newly diagnosed AML ineligible for intensive chemotherapy? Which of the emerging regimens do you think will be most important? (42:06)Based on the latest research presented at EHA 2022, which prognostic tools and biomarkers do you consider most promising to support treatment decisions in HR-MDS or newly diagnosed AML? (49:55)This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.
For further information visit our website: https://touchoncology.com/education/MDS-AML-EHA2022-touchcongress/